GRCE
Grace Therapeutics, Inc. · Healthcare · Market cap $41.4M
Insiders bought $616K net in the last 90 days ·0 sellers, 2 buyers· latest Form 4 filed Oct 21, 2026
Insider Buying
$616K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Latest filing
Oct 21, 2026
Opaleye Management Inc.
Grace Therapeutics, Inc. (GRCE) has 10 SEC Form 4 filings (19 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Oct 21, 2026.
Inside the rolling window, 2 insiders at Grace Therapeutics, Inc. reported 17 open-market purchases totaling $616K and no open-market sales. The most active filer is 10% Owner Opaleye Management Inc. with 16 filings. Insiders have net bought $616K over the trailing 6 months. The most recent open-market filing is a purchase of 4,256 shares by 10% Owner Opaleye Management Inc., dated Oct 19, 2026, worth $8K.
- Industry:Biotechnology
- CEO:Prashant Kohli
- Employees:5
- HQ:Princeton, NJ, US
- IPO:2012-02-07
| Source | |||||||
|---|---|---|---|---|---|---|---|
| 10% Owner | Purchase | 4,256 | $8K | Oct 21 | — | SEC ↗ | |
| 10% Owner | Purchase | 11,233 | $22K | Oct 17 | +4.8% | SEC ↗ | |
| 10% Owner | Purchase | 23,485 | $46K | Oct 17 | +4.8% | SEC ↗ | |
| 10% Owner | Purchase | 36,347 | $69K | Oct 17 | +4.8% | SEC ↗ | |
| 10% Owner | Purchase | 2,077 | $4K | Oct 13 | -1.0% | SEC ↗ | |
| 10% Owner | Purchase | 5,340 | $11K | Oct 13 | -1.0% | SEC ↗ | |
| 10% Owner | Purchase | 7,215 | $15K | Oct 13 | -1.0% | SEC ↗ | |
| 10% Owner | Purchase | 38,796 | $79K | Oct 5 | -4.4% | SEC ↗ | |
| 10% Owner | Purchase | 20,000 | $41K | Oct 5 | -4.4% | SEC ↗ | |
| 10% Owner | Purchase | 1,694 | $3K | Oct 5 | -4.4% | SEC ↗ | |
| 10% Owner | Purchase | 9,771 | $21K | Oct 1 | — | SEC ↗ | |
| 10% Owner | Purchase | 5,318 | $11K | Oct 1 | — | SEC ↗ | |
| 10% Owner | Purchase | 7,849 | $16K | Oct 1 | — | SEC ↗ | |
Kohli PrashantFirst filing | Chief Executive Officer | Purchase | 100,000 | $214K | Sep 10 | — | SEC ↗ |
| 10% Owner | Purchase | 9,393 | $20K | Sep 10 | — | SEC ↗ | |
| 10% Owner | Purchase | 5,836 | $12K | Sep 10 | — | SEC ↗ | |
| 10% Owner | Purchase | 11,608 | $24K | Aug 19 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does GRCE have?
Grace Therapeutics, Inc. (GRCE) has 10 SEC Form 4 filings (19 transaction rows) in the rolling 365-day window, disclosed by 2 distinct insiders. Most recent filing: Oct 21, 2026.
When was the most recent SEC Form 4 filing for GRCE?
The most recent Form 4 filing for GRCE on Tracefour is dated Oct 21, 2026.
Who is the most active insider at GRCE?
The most active SEC Form 4 filer at GRCE in the rolling window is 10% Owner Opaleye Management Inc., with 16 filings.
What is the net insider flow at GRCE over the last 6 months?
Over the trailing 180 days, insiders at GRCE have net bought $616K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at GRCE in the current window?
Inside the rolling window, insiders at GRCE bought $616K and sold $0 based on SEC Form 4 filings.
Can I get alerts for GRCE insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Grace Therapeutics, Inc. (GRCE). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Grace Therapeutics, Inc. is in the Healthcare sector.